Strategies in Accurately Assessing Penile Curvature
Rafael E. Carrion, MD

Point/Counterpoint: Excision and Grafting: A Dying Procedure
Laurence A. Levine, MD
Jason M. Greenfield, MD

Point/Counterpoint: Injection Therapy is the Best Non-Surgical Management for Peyronie's Disease
Lawrence S. Hakim, MD, FACS
Martin K. Gelbard, MD

Panel Q & A

Current Treatment Options for Premature Ejaculation
Stanley Althof, PhD, IF

Diagnosis and Management of Pelvic Pain
Robert M. Moldwin, MD

Q & A

Central Control of FSD and PGAD
James G. Pfaus, PhD

Vaginal and Clitoral Basic Science Review
Noel Kim, PhD

Sexual Pain and Surgery
Andrew T. Goldstein, MD, IF

HRT Considerations - New Data for Vulvovaginal Atrophy
James A. Simon, MD, IF

Panel Discussion/Q&A

Combination PDE5-i Use: Efficacy, Safety, Practice Patterns
Hossein Sadeghi-Nejad, MD, FACS

Managing Patients with Venous Leak
Kenneth Mitchell, MPAS, PA-C

Infection Prevention and Management in Prosthetic Surgery Updaten "North American Consensus Document on Infection of Penile Prostheses (NACDIPP)"
Rabih Darouiche, MD

Panel Discussion
Andrew C. Kramer, MD
John J. Mulcahy, MD
Steven K. Wilson, MD
Gerard D. Henry, MD
Paul E. Perito, MD
Culley C. Carson III, MD
Laurence A. Levine, MD
Francois Eid, MD

Developing Champions in Sexual Medicine: Update on the Summit on Medical School Education in Sexual Health
Sue W. Goldstein, BA, IF
Kevin L. Billups, MD

Training the Next Generation of Sexual Medicine Clinicians
Andrew C. Kramer, MD

Socioeconomic Update
William F. Gee, MD

Panel Q & A

083 ORAL ENCLOMID (ANDROXAL) RAISES FREE AND TOTAL SERUM TESTOSTERONE IN HYPOGONADAL MEN: COMPARISON WITH A TOPICAL GEL
Gregory Fontenot, PhD

084 ORAL ENCLOMID (ANDROXAL) RAISES SERUM TESTOSTERONE AND ESTROGEN IN HYPOGONADAL MEN AND MAY HAVE FAVORABLE EFFECTS ON BONE MINERAL DENSITY
Gregory Fontenot, PhD

085 THE CUPPID TRIAL: CARDIOLOGY CLINIC PATIENTS ARE AT HIGH RISK FOR SYMPTOMATIC HYPOGONADISM
Bradford Stevenson, MD

086 FREE TESTOSTERONE BY DIRECT AND CALCULATED MEASUREMENT VERSUS EQUILIBRIUM DIALYSIS IN A CLINICAL POPULATION
Ravi Kacker, MD

087 BONE MINERAL DENSITY AND RESPONSE TO TREATMENT IN TESTOSTERONE DEFICIENT MEN YOUNGER THAN 50 YEARS OLD
Ravi Kacker, MD

088 INCREASED BODY FAT IS ASSOCIATED WITH HIGHER LH LEVELS IN TESTOSTERONE-DEFICIENT MEN
Ravi Kacker, MD

089 THE CORRELATION BETWEEN BODY MASS INDEX AND EFFECTIVE TESTOSTERONE REPLACEMENT
Jessie Gills, MD

090 DOES HYPOGONADISM CONTRIBUTE TO RECURRENT URETHRAL STRICTURE DISEASE?
Clay Mechlin, MD, MS

091 TIMING OF IMPROVEMENT IN LUTS WITH TESTOSTERONE SUPPLEMENTATION WITHIN THE FIRST SIX MONTHS OF THERAPY
Charles Welliver, MD

092 VASECTOMY REVERSAL OUTCOMES IN MEN PREVIOUSLY ON TESTOSTERONE REPLACEMENT THERAPY
Douglas Mata, MPH

093 LOW TOTAL TESTOSTERONE (TT) IS ASSOCIATED WITH HIGHER MORTALITY IN MEN WITH STAGES 3-5 CHRONIC KIDNEY DISEASE (CKD)
Daniel Shoskes

094 CAN TREATMENT OF NOCTURIA INCREASE TESTOSTERONE LEVEL IN MEN WITH LATE ONSET HYPOGONADISM?
Jong Wook Kim, PhD

095 ADDING THE AROMATASE INHIBITOR ANASTROZOLE (AZ) TO TESTOSTERONE PELLET (TP) THERAPY PROLONGS THERAPEUTIC TESTOSTERONE (T) LEVELS AND TIME BETWEEN TP INSERTIONS: AN OBSERVATIONAL RETROSPECTIVE STUDY
Clay Mechlin, MD, MS

096 ASSOCIATION BETWEEN DEPRESSION AND HYPOGONADISM IN MIDDLE-AGED MEN
Cynara Maceda, MD

097 RETROSPECTIVE STUDY OF THE EFFECT OF ANDROGEL TREATMENT IN HYPOGONADISM ON CONCOMITANT MEDICATION DISCONTINUATION
Amit Bodhani

098 SALVAGE PHARMACOTHERAPY FOR ORGASMIC DYSFUNCTION AFTER TREATMENT FOR TESTOSTERONE DEFICIENCY
Ravi Kacker, MD

099 THE IMPACT ON HYPOGONADAL SYMPTOMS OF SWITCHING FROM CLOMIPHENE CITRATE (CC) TO TRANSDERMAL TESTOSTERONE (TDT)
Boback Berookhim, MD, MBA

100 SAFETY OF TESTOSTERONE THERAPY IN MEN WITH PROSTATE CANCER
Ravi Kacker, MD

101 EFFICACY OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR TREATMENT OF PEYRONIE'S DISEASE BY BASELINE PENILE CURVATURE SEVERITY: TWO LARGE DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
Larry I. Lipshultz, MD

102 THE EFFECT OF ADJUNCT PENILE TRACTION THERAPY ON CURVATURE, LENGTH, AND CIRCUMFERENCE IN PATIENTS UNDERGOING INTRALESIONAL INJECTION WITH INTERFERON ALPHA-2B FOR PEYRONIE'S DISEASE
Gregory C. Mitchell, MD, MS

103 DIABETIC AND NON-DIABETIC PEYRONIE'S PATIENTS: EVALUATION OF PRESENTING SYMPTOMS, SURGICAL MANAGEMENT AND OUTCOMES
Stephen Larsen

104 PHASE 3, OPEN-LABEL STUDY OF THE SAFETY AND EFFECTIVENESS OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN MEN WITH PEYRONIE'S DISEASE
Laurence A. Levine, MD

105 SAFETY PROFILE OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN THE TREATMENT OF PEYRONIE'S DISEASE WHEN PENILE CURVATURE ?30 OR <30: TWO DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
Wayne J.G. Hellstrom, MD

106 LONG-TERM OUTCOMES AND PATIENT SATISFACTION AFTER YACHIA CORPOROPLASTY FOR PEYRONIE'S DISEASE: A SINGLE INSTITUTIONAL REVIEW
John M. Kelley

107 CLINICAL EVALUATION OF TREATMENT OF PEYRONIE'S DISEASE WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM: ANALYSIS OF PENILE CURVATURE DEFORMITY BY DURATION OF DISEASE AND PLAQUE CALCIFICATION
Irwin Goldstein, MD

108 INTEGRATED SAFETY PROFILE OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN CLINICAL STUDIES EVALUATING THE TREATMENT OF PEYRONIE'S DISEASE
Culley C. Carson III, MD

109 DORSAL PLICATION WITHOUT DEGLOVING FOR CORRECTION OF ADULT VENTRAL PENILE DEFORMITIES
Paul H. Chung, MD

110 DETERMINATION OF THE PARENTAL KNOWLEDGE AND BEHAVIORAL PATTERN ON CIRCUMCISION
Ilhami Surer, MD

111 CROSS-SECTIONAL ANALYSIS OF PENDULOUS, STRETCHED, AND ERECT PENILE LENGTH MEASUREMENTS IN PEYRONIE'S DISEASE
Wayne J.G. Hellstrom, MD

112 EARLY VERSUS LATE IMPROVEMENT WITH INTRALESIONAL VERAPAMIL THERAPY TO TREAT PEYRONIE'S DISEASE
Vikram Soni, MD

113 CLINICAL OUTCOMES OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN THE TREATMENT OF SUBJECTS WITH PEYRONIE'S DISEASE BY SUBGROUPS: TWO LARGE DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDIES
Arthur L. Burnett II, MD

114 ERECTILE DYSFUNCTION SECONDARY TO PENILE ARTERY STEAL SYNDROME (PASS)
Tariq S. Hakky, MD

115 VASECTOMY REVERSAL FOR SEXUAL SYMPTOMS FOLLOWING VASECTOMY
Mary Samplaski, MD

116 SURVEY OF INTERNATIONAL SOCIETY OF SEXUAL MEDICINE MEMBERS: USE PATTERNS FOR THE VACUUM ERECTION DEVICE
Hossein Sadeghi-Nejad, MD, FACS

117 MODERN UTILIZATION OF PENILE PROSTHESIS SURGERY: A NATIONAL CLAIMS REGISTRY ANALYSIS
Robert Segal, MD, FRCS(C)

118 BONE SAW FOR CALCIFIED PEYRONIE'S DISEASE PLAQUES
Kevin A. Ostrowski, MD

119 DIRECT EFFECTS OF TADALAFIL ON LOWER URINARY TRACT SYMPTOMS VS INDIRECT EFFECTS MEDIATED THROUGH ERECTILE DYSFUNCTION SYMPTOM IMPROVEMENT: INTEGRATED ANALYSES OF 4 PLACEBO-CONTROLLED CLINICAL STUDIES
Gerald Brock, MD, FRCS

120 TREATMENT OF LUTS SECONDARY TO BPH WHILE PRESERVING SEXUAL FUNCTION: RANDOMIZED CONTROLLED STUDY OF PROSTATIC URETHRAL LIFT
Kevin McVary, MD, FACS

121 EFFECTS OF THE ONCE DAILY CO ADMINISTRATION OF TADALAFIL WITH FINASTERIDE FOR 6 MONTHS IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND PROSTATIC ENLARGEMENT SECONDARY TO BENIGN PROSTATIC HYPERPLASIA
Hartwig Bttner, MD

122 EFFICACY OF TADALAFIL ONCE DAILY FOR TREATMENT OF ERECTILE DYSFUNCTION: THE INFLUENCE OF TESTOSTERONE LEVELS
Evan Goldfischer, MD, MBA

123 SATISFACTION WITH TADALAFIL OR TAMSULOSIN ONCE DAILY FOR THE TREATMENT OF LUTS/BPH: TREATMENT SATISFACTION SCALE QUESTIONNAIRE RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Angelina Sontag, PhD

124 RANDOMIZED, CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF SILDENAFIL FOR THE TREATMENT OF RECURRENT ISCHEMIC PRIAPISM ASSOCIATED WITH SICKLE CELL DISEASE
Arthur L. Burnett II, MD

125 ERECTOGENIC EFFECT OF AVANAFIL WITHIN 15 MINUTES OF DOSING IN MEN WITH MILD TO SEVERE ERECTILE DYSFUNCTION
Irwin Goldstein, MD

126 EFFICACY OF AS NEEDED PDE5 INHIBITOR THERAPY VS. TADALAFIL ONCE DAILY ON IMPROVEMENT IN ERECTILE DYSFUNCTION
Edward Kim, MD

127 AN INVESTIGATION ON CURRENT STATUS AND PUBLIC AWARENESS FOR COUNTERFEIT PHOSPHODIESTERASE TYPE 5 INHIBITORS IN KOREA
Sang-Kuk Yang, MD, PhD

128 ROLE OF NOCTURNAL PENILE TUMESCENCE AND RIGIDITY IN RESPONSE TO DAILY SILDENAFIL IN PATIENTS WITH ERECTILE DYSFUNCTION DUE TO PELVIC FRACTURE URETHRAL DISRUPTION: A SINGLE-CENTER EXPERIENCE
Jing Peng, MD

129 EFFECTS OF DEODORANT AND ANTIPERSPIRANT USE AND THE ABSENCE OF HAIR ON THE ABSORPTION OF TESTOSTERONE 2% SOLUTION APPLIED TO THE AXILLAE
Paula Polzer,

130 CHANGE IN SEXUAL FUNCTION IN MEN WITH LUTS/BPH ASSOCIATED WITH LONG-TERM TREATMENT WITH DOXAZOSIN, FINASTERIDE, AND COMBINED THERAPY
Kevin McVary, MD, FACS

131 EFFICACY OF TADALAFIL ONCE DAILY IN MEN WITH ERECTILE DYSFUNCTION: AN INTEGRATED ANALYSIS OF DATA OBTAINED FROM 1,913 PATIENTS FROM 6 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL STUDIES
Hartwig Bttner, MD

132 IMPROVEMENT IN PENILE CURVATURE AND PLAQUE VOLUME AFTER INTRALESIONAL VERAPAMIL THERAPY AS A FUNCTION OF PEYRONIE'S DISEASE SEVERITY
Saneal Rajanahally,

133 MODIFICATION OF THE INVANCE MALE SLING PROCEDURE: TREATMENT OF STRESS INCONTINENCE AFTER RADICAL PROSTATECTOMY
Bashar Omarbasha, MD

134 NEUROPHYSIOLOGIC TESTING IN MEN COMPLAINING OF PENILE SEANTION LOSS AFTER FINASTERIDE USE FOR HAIR LOSS
John Sullivan, MD

135 THE AROMATASE INHIBITOR (AI) ANASTRAZOLE (AZ) INCREASES THE DURATION OF THERAPEUTIC TESTOSTERONE (T) LEVELS AFTER TESTOSTERONE PELLET (TP) INSERTIONS: A RETROSPECTIVE LONGITUDINAL STUDY
Clay Mechlin, MD, MS

136 THE EFFECT OF CLOMIPHENE CITRATE ON INFERTILE MALES
Jason Kovac, MD, PhD

137 THE MINIMALLY INVASIVE, NO-TOUCH (MINT) TECHNIQUE FOR PENILE IMPLANT SURGERY
Christopher Love, MBBS

138 OUTCOMES OF ABDOMINAL WALL RESERVOIR PLACEMENT IN INFLATABLE PENILE PROSTHESIS IMPLANTATION: A SAFE AND EFFICACIOUS ALTERNATIVE TO THE SPACE OF RETZIUS
Doron S. Stember, MD

141 IATROGENIC URETHRAL INJURY DURING PLACEMENT OF PENILE PROSTHESIS, IS IT TRULY AN INDICATION TO ABORT?
Daniel Martinez, MD

142 INITIAL TWO YEAR EXPERIENCE WITH HIGH SUBMUSCULAR PLACEMENT OF INFLATABLE PENILE PROSTHESIS RESERVOIRS
Allen F. Morey, MD

143 ECTOPIC RESERVOIR PLACEMENT DOES NOT INCREASE RISK OF IPP COMPLICATIONS
Tobias Kohler, MD, MPH

144 INCREASE IN AVERAGE AGE OF INFLATABLE PENILE PROTHESIS RECIPIENTS OVER THE PAST 13 YEARS
Doron S. Stember, MD

145 THE CARRION CAST: AN INTRACORPORAL ANTIMICROBIAL SPACER MADE OF CASO4 USED TO BRIDGE THE GAP BETWEEN EXPLANTATION OF INFECTED PENILE PROSTHESIS AND DELAYED REIMPLANTATION
Daniel Martinez, MD

146 PERINEAL MINIMALLY INVASIVE TECHNIQUE FOR CYLINDER LENGTH ADJUSTMENT
Seth D. Cohen, MD, MPH

147 HIGH SUBMUSCULAR VERSUS SPACE OF RETZIUS PLACEMENT OF IPP RESERVOIRS: WHAT ARE SURGEONS SAYING?
Allen F. Morey, MD

148 INFLATABLE PENILE PROSTHESIS TECHNIQUE AND OUTCOMES AFTER RADIAL FOREARM FREE FLAP NEOPHALLOPLASTY
Robert Segal, MD, FRCS(C)

149 EXTERNAL TRACTION THERAPY FOR PENILE LENGTH RECOVERY PRIOR TO PROSTHESIS REPLACEMENT- A PROOF OF CONCEPT STUDY
Benjamin Sherer, MD

150 HIGH PATIENT SATISFACTION OF INFLATABLE PENILE PROSTHESIS WITH SYNCHRONOUS PLICATION FOR CORRECTION OF PEYRONIE'S DISEASE WITH ERECTILE DYSFUNCTION
Paul H. Chung, MD

151 CORPOROTOMY PLUG TECHNIQUE IN THE MANAGEMENT OF PROXIMAL CORPORAL PERFORATION DURING REVISION PENILE PROSTHESIS SURGERY
Tariq S. Hakky, MD

152 EFFICACY OF PENILE TRACTION THERAPY AMONG PATIENTS UNDERGOING INTRALESIONAL INTERFERON TREATMENT FOR PEYRONIE'S DISEASE
Wayne J.G. Hellstrom, MD

153 TRENDS IN SURGICAL APPROACH OF PENILE PROTHESIS SURGERY OVER THE PAST 13 YEARS
Doron S. Stember, MD

154 SHORTENED PENIS POST PENILE PROSTHESIS IMPLANTATION TREATED WITH SUBCUTANEOUS SOFT SILICONE PENILE IMPLANT: CASE STUDY
Vaheh Shirvanian, MD